Iridex IRIX
Iridex FY 2023: revenue $51.9M, down 9%; diluted EPS −$0.59
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-038650
- Document
- 10-K
Key figures from this report
These are the numbers Iridex reported for the year ended Dec 30, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$51.9M−9% from $57.0M in FY 202210-K income statement, on EDGAR
- Net income−$9.6MAgainst −$7.5M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$0.59Against −$0.47 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$7.0M−49% from $13.9M in FY 202210-K balance sheet, on EDGAR
- Cash from operations−$6.7MAgainst −$9.5M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.
- Nexalin Technology NXL public float $15M, Jun 30, 2025
- Biotricity BTCY public float $13M, Sep 30, 2025
- Beyond Air XAIR public float $16M, Sep 30, 2025
- RetinalGenix Technologies RTGN public float $16M, Jun 30, 2025
- Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025
